探索癌症

111病人參與實驗
58% 腫瘤有PDL1表象
15.6% 五人有3級以上不良事件 包括一人因治療死亡
反應率18.5%
反應發生時間 7週至32週

Results Among 111 patients with TNBC whose tumor samples were screened for PD-L1 expression, 58.6% had PD-L1–positive tumors. Thirty-two women (median age, 50.5 years; range, 29 to 72 years) were enrolled and assessed for safety and antitumor activity. The median number of doses administered was five (range, 1 to 36 doses). Common toxicities were mild and similar to those observed in other tumor cohorts (eg, arthralgia, fatigue, myalgia, and nausea), and included five (15.6%) patients with grade ≥ 3 toxicity and one treatment-related death. Among the 27 patients who were evaluable for antitumor activity, the overall response rate was 18.5%, the median time to response was 17.9 weeks (range, 7.3 to 32.4 weeks), and the median duration of response was not yet reached (range, 15.0 to ≥ 47.3 weeks).

http://jco.ascopubs.org/content/early/2016/04/27/JCO.2015.64.8931.abstract

58% 腫瘤有PDL1表象　顯示三陰性乳癌是適合使用ＰＤ１抑制劑的
未來兩年許多乳癌ＰＤ１抑制劑臨床實驗結果出爐
讓我們更瞭解
Ａ）ＰＤ１抑制劑如何與化放療使用　能減輕病人治療痛苦並得到持久療效
Ｂ）哪些病人適合使用ＰＤ１抑制劑　哪些病人不適合使用ＰＤ１抑制劑